268 related articles for article (PubMed ID: 31987017)
21. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
22. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
[TBL] [Abstract][Full Text] [Related]
23. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
Donnez J; Courtoy GE; Donnez O; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
[TBL] [Abstract][Full Text] [Related]
24. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
25. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.
Biglia N; Carinelli S; Maiorana A; D'Alonzo M; Lo Monte G; Marci R
Drug Des Devel Ther; 2014; 8():285-92. PubMed ID: 24591818
[TBL] [Abstract][Full Text] [Related]
26. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Kolanska K; Varinot J; Canlorbe G; Bergeron C; Mekinian A; Capmas P; Koskas M; Daraï E; Aractingi S; Bendifallah S; Chabbert-Buffet N
Reprod Biomed Online; 2019 May; 38(5):825-834. PubMed ID: 30898512
[TBL] [Abstract][Full Text] [Related]
27. Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients' compliance.
Tinelli A; Gustapane S; D'Oria O; Licchelli M; Panese G
Int J Gynaecol Obstet; 2022 Jan; 156(1):133-138. PubMed ID: 33797759
[TBL] [Abstract][Full Text] [Related]
28. Ulipristal acetate in symptomatic uterine fibroids. A real-world experience in a multicentric Italian study.
Giarrè G; Franchini M; Castellacci E; Malune ME; Di Spiezio Sardo A; Saccone G; Angioni S
Gynecol Endocrinol; 2020 Feb; 36(2):171-174. PubMed ID: 31392917
[TBL] [Abstract][Full Text] [Related]
29. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.
Melis GB; Piras B; Marotto MF; Orru' MM; Maricosu G; Pilloni M; Guerriero S; Angiolucci M; Lello S; Paoletti AM
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):901-8. PubMed ID: 22681335
[TBL] [Abstract][Full Text] [Related]
31. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
32. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
[TBL] [Abstract][Full Text] [Related]
34. Emerging treatment options for uterine fibroids.
Donnez J; Arriagada P; Donnez O; Dolmans MM
Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
[TBL] [Abstract][Full Text] [Related]
35. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
36. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract][Full Text] [Related]
37. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
[TBL] [Abstract][Full Text] [Related]
39. Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France.
Fernandez H; Jourdain O; Villefranque V; Lehmann M; Lafuma A; Trancart M
BMJ Open; 2017 Sep; 7(9):e015571. PubMed ID: 28871011
[TBL] [Abstract][Full Text] [Related]
40. Ulipristal acetate--a review of the new therapeutic indications and future prospects.
Delev DP
Folia Med (Plovdiv); 2013; 55(3-4):5-10. PubMed ID: 24712276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
